Impact of Cold Ischemia Time on Outcomes of Deceased Donor Kidney Transplantation:An Analysis of a National Registry by Peters-Sengers, Hessel et al.
  
 University of Groningen
Impact of Cold Ischemia Time on Outcomes of Deceased Donor Kidney Transplantation
Peters-Sengers, Hessel; Houtzager, Julia H E; Idu, Mirza M; Heemskerk, Martin B A; van
Heurn, Ernst L W; Homan van der Heide, Jaap J; Kers, Jesper; Berger, Stefan P; van Gulik,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Peters-Sengers, H., Houtzager, J. H. E., Idu, M. M., Heemskerk, M. B. A., van Heurn, E. L. W., Homan van
der Heide, J. J., ... Bemelman, F. J. (2019). Impact of Cold Ischemia Time on Outcomes of Deceased
Donor Kidney Transplantation: An Analysis of a National Registry. Transplantation direct, 5(5), [e448].
https://doi.org/10.1097/TXD.0000000000000888
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
Transplantation DIRECT   ■   2019 www.transplantationdirect.com 1
The Dutch Organ Transplantation Registry (NOTR) was funded and 
administered by the Dutch Transplantation Foundation (NTS), with initial 
additional funding from the Dutch Health Care Insurance Board (CVZ). 
The funding sources had no role in the study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding 
author had full access to the data and final responsibility for the decision to 
submit for publication.
Supplemental digital content (SDC) is available for this article. Direct URL 
citations appear in the printed text, and links to the digital files are provided in the 
HTML text of this article on the journal’s Web site (www.transplantationdirect.
com).
Correspondence: H. Peters-Sengers, Department of Nephrology and Kidney 
Transplantation, Academic Medical Center (AMC), Room A3-274, Meibergdreef 
9, 1105 AZ Amsterdam, the Netherlands. (h.peterssengers@amc.uva.nl).
Copyright © 2019 The Author(s). Transplantation Direct. Published by Wolters 
Kluwer Health, Inc. This is an open-access article distributed under the terms of 
the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 
(CCBY-NC-ND), where it is permissible to download and share the work provided 
it is properly cited. The work cannot be changed in any way or used commercially 
without permission from the journal.
ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000888
Received 1 August 2018. Revision received 21 January 2019.
Accepted 24 February 2019.
1 Department of Nephrology,  Amsterdam UMC, University of Amsterdam, 
Amsterdam, the Netherlands.
2 Center for Experimental Molecular Medicine (CEMM), Amsterdam UMC, 
University of Amsterdam, Amsterdam, the Netherlands.
3 Department of Surgery,  Amsterdam UMC, University of Amsterdam, 
Amsterdam, the Netherlands.
4 Dutch Transplant Foundation, Leiden, the Netherlands.
5 Department of Pathology, Amsterdam UMC, University of Amsterdam, 
Amsterdam, the Netherlands.
6 Department of Nephrology, University of Groningen, University Medical Center 
Groningen, Groningen, the Netherlands.
H.P.-S. and J.H.E.H. contributed equally to the study.
The authors declare no conflicts of interest.
H.P.-S., J.H.E.H., M.M.I., T.M.v.G., and F.J.B. were involved in the design of 
the study. H.P.S. did the statistical analysis and drafted the article together with 
J.H.E.H., whereas all authors took part in the data interpretation and its revision. 
Each author contributed important intellectual content during manuscript 
drafting or revision and accepts accountability for the overall work by ensuring 
that questions pertaining to the accuracy or integrity of any portion of the work 
are appropriately investigated and resolved.
Impact of Cold Ischemia Time on Outcomes  
of Deceased Donor Kidney Transplantation:  
An Analysis of a National Registry
Hessel Peters-Sengers, PhD,1,2 Julia H.E. Houtzager, Msc,3 Mirza M. Idu, MD, PhD,3  
Martin B.A. Heemskerk, PhD,4 Ernst L.W. van Heurn, MD, PhD,3 Jaap J. Homan van der Heide, MD, PhD,1 
Jesper Kers, MD, PhD,5 Stefan P. Berger, MD, PhD,6 Thomas M. van Gulik, MD, PhD,3  
and Frederike J. Bemelman, MD, PhD1
Kidney Transplantation
Background. Cold ischemia time (CIT) is known to impact kidney graft survival rates. We compare the impact of 
CIT on graft failure and mortality in circulatory death versus brain death donor kidneys and how it relates to donor age. 
Methods. We used the prospective Dutch Organ Transplantation Registry to include 2153 adult recipients of brain death 
(n = 1266) and circulatory death (n = 887) donor kidneys after static cold storage from transplants performed between 2005 
and 2012. CIT was modeled nonlinearly with splines. Associations and interactions between CIT, donor type, donor age, 
5-year (death-censored) graft survival, and mortality were evaluated. Results. The median CIT was 16.2 hours (inter-
quartile range 12.8–20), ranging from 3.4 to 44.7 hours for brain death and 4.7 to 46.6 hours for circulatory death donor 
kidneys. At >12 hours of CIT, we observed an increased risk of graft failure in kidneys donated after circulatory death versus 
after brain death. This risk rose significantly at >22 hours of CIT (hazard ratio 1.45; 95% confidence interval, 1.01-2.49; P = 
0.043). Kidneys that came from 60-year-old circulatory death donors demonstrated elevated hazard risk at 19 hours of CIT, a 
shorter timeline than that for kidneys that came from brain death donors of the same age (hazard ratio 1.33; 95% confidence 
interval, 1.00-1.78; P = 0.045). The additional harmful effects of increased CIT in kidneys from circulatory-death donors were 
also found for death-censored graft failure but did not affect mortality rates in any significant way.  Conclusions. The 
findings support the hypothesis that prolonged cold ischemia is more harmful for circulatory death donor kidneys that have 
already been subjected to a permissible period of warm ischemia. Efforts should be made to reduce CIT, especially for older 
circulatory death donor kidneys.
(Transplantation Direct 2019;5:e448; doi: 10.1097/TXD.0000000000000888. Published online 25 April, 2019.)
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Donor shortages have led to increased use of kidneys from donation after circulatory death (DCD).1 In 
the Netherlands, nearly all such donations are classified as 
controlled.2 These are patients for whom further treatment 
is suspected to be futile, with the result that withdrawal of 
life-sustaining treatment is initiated in the intensive care unit 
and circulatory arrest is awaited. In contrast to donation 
after brain death (DBD) kidneys, DCD kidneys suffer from 
additional warm ischemic injury caused by the lack of blood 
perfusion of these organs during the agonal phase and after 
circulatory arrest. Once explanted, donor kidneys are pre-
served for transport, either by static cold storage on ice or 
machine perfusion.
Static cold storage lowers the temperature of the graft to 
0°C to 4°C with the aim of preventing ischemic reperfusion 
injury. Prolonged exposure to either warm or cold ischemia 
depletes adenosine triphosphate levels, leading to a build-up 
of reactive oxygen species and inflammation and coagulation 
after reperfusion, which causes renal tubular cell damage and 
thus increases the risk of graft failure.3-5 However, it remains 
unclear what impact each extra hour of cold ischemia time 
(CIT), the time from the cold flushing of the donor organ until 
the graft is implanted into the recipient, has on graft outcome 
and whether any impact differs between donor types (ie, DCD 
vs DBD) and ages.
Summers et al6 found that, in a large UK cohort (2005–
2010), prolonged CIT was associated with reduced kidney 
graft survival in recipients of DCD kidneys and higher donor 
age was associated with earlier graft failure for both DCD 
and DBD donor kidneys. However, this study analyzed CIT 
categorically, leaving the exact point during the CIT window 
at which the risk of graft failure increases for DCD kidneys 
undetermined. An animal study found that, after 24 hours of 
CIT, energy substrates become depleted such that they could 
not recover at reperfusion, leading to lethal cellular injury.7 
However, a recent US retrospective DCD paired kidney 
analysis (n = 6276), which controlled for all possible donor 
confounders, did not find an association between CIT and 
death-censored graft failure.8 These differing findings con-
cerning the impact of CIT make it difficult to formulate any 
universal guidelines. Determining clear cutoff values for CIT 
could aid transplant professionals in estimating the quality 
of a donor kidney and help to safely expand the donor pool.
In this registry-based Dutch cohort study, we (1) analyze 
the association between CIT and renal graft failure and mor-
tality, (2) investigate whether this association is different for 
DCD kidneys as compared with DBD kidneys, and (3) explore 
the hazard ratios (HRs) for each extra hour of CIT in both 
donor types and relate these findings to donor age.
MATERIALS AND METHODS
Study Population
The Dutch Organ Transplant Registry (NOTR), a nation-
wide prospective registry maintained by the Dutch Transplant 
Foundation, records kidney transplant follow-up data from all 
8 transplantation centers in the Netherlands, including the date 
of recipient death after allograft failure. We included recipients 
(n = 2153) 18 years or older who received a first kidney from 
a DBD donor or controlled DCD donor9 between January 1, 
2005, and January 1, 2012. The final follow-up date was May 
1, 2015. Kidneys allocated to overseas patients are preserved 
by machine perfusion and thus excluded from the analysis. 
Adult recipients of kidneys from donors aged 10 years and 
younger were excluded, as were any patients who received 
donor kidneys either en bloc or as a dual transplant. No donors 
demonstrated hepatitis C virus positivity. Donor kidneys were 
acquired through allocation by the Eurotransplant Senior 
Program (ESP), which is based on Leiden, the Netherlands.9 
Detailed descriptions of DBD and DCD donor procedures 
and recipient immunosuppression regimens are included in 
the supplemental section of this article (Figure S1A and B, 
SDC, http://links.lww.com/TXD/A202). Research studies 
based on the NOTR fall under transplant assessment activ-
ity and therefore do not require institutional review board 
approval. Additionally, all data were anonymized by the Dutch 
Transplant Foundation. The study was conducted in accord-
ance with Dutch law as is consistent with the Principles of 
the Declaration of Istanbul as outlined in the “Declaration of 
Istanbul on Organ Trafficking and Transplant Tourism.”
Outcome Measures
We evaluated 5-year graft survival rates (defined as patient 
death or graft loss leading to dialysis treatment, whichever 
comes first) and death-censored graft survival. In addition, to 
analyze patient survival, we included the date of death for 
patients who experienced graft loss.
Data Analyses
Continuous variables are presented as median ± interquar-
tile range (IQR). Continuous variables across the DBD and 
DCD were compared using independent t-tests (or nonpar-
ametric Mann-Whitney U tests if appropriate) and 2-tailed 
Fisher exact statistics for categorical variables. Cumulative 
incidence competing risk functions were used to calculate 
unadjusted incidences of 5-year graft survival and take into 
account the competing events of patient death and graft loss.10 
Kaplan-Meier curves were used to estimate patient survival, 
and cause-specific Cox regression analyses were conducted 
to take into account possible confounders in the association 
between CIT and graft failure, death-censored graft failure, 
and mortality. For these 3 outcomes, the hazards were pro-
portional over time; this was tested by defining the 2 donor 
types as a function of the time variable, which was divided 
into 2 equal periods (first 2.5-y vs last 2.5-y follow-up). For 
the restricted cubic spline analysis, 4 knots were considered 
based on the Akaike information criterion;11 the knots were 
placed at 12, 16, 20, and 24 hours of CIT based on expert 
opinions and sufficient sample size at the knots for both DBD 
and DCD. Wald tests were used to describe the association 
of CIT with outcome and by testing for linearity. Depending 
on test of linearity, the presence of interaction of CIT and 
donor type was evaluated by adding an interaction term with 
or without 4-knot restricted splines, and Wald tests were used 
to estimate the joint association of the interactions. The fol-
lowing were considered as potential confounders: (a) donor 
gender, (b) donor hypertension (treated) (no/yes), (c) donor’s 
terminal creatinine (mg/dL), (d) donor’s use of tobacco (no/
yes), (e) use of inotropic drugs before donation (no/yes), (f) 
donor height, (g) donor weight, (h) donor’s diabetes status, 
(i) donor’s cause of death, (j) donor age, (k) anastomosis time 
(min), (l) human leukocyte antigen-A (HLA-A), HLA-B, and 
HLA-DR mismatch levels, (m) recipient gender, (n) recipient 
age, (o) recipient’s diabetes status, (p) recipient body mass 
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index, (q) recipient hypertension, (r) recipient’s panel reactive 
antibodies at the time of transplantation (%), (s) dialysis vin-
tage (y), (t) recipient’s primary renal disease, and (u) donor 
and recipient listed within the ESP (no/yes). The recipient’s 
primary renal disease leading to renal failure was categorized 
as polycystic kidney disease (reference), glomerulonephritis, 
renal vascular disease, diabetes, chronic renal failure (etiology 
unknown), pyelonephritis, or other. The kidney donor risk 
index donor-only version12 was calculated assuming a white 
population. For models that included only circulatory death 
donor kidneys, first warm ischemic time (first WIT), defined as 
the time from circulatory arrest to cold perfusion, was added. 
Each donor, transplant, and recipient characteristic had 
<12.4% missing information; missing values were imputed 
using a multivariate imputation by chained equations algo-
rithm with a predictive mean matching modeling type.13 To 
take different imputed values into account using appropriate 
methods, 20 imputed datasets with 30 iterations were each 
created and the estimates combined.14
The following 4 analyses were performed: a comparison 
of the association of CIT with outcome between donor types 
using the DBD donor kidneys as the reference category; an 
analysis of the association of CIT with outcomes separated 
(stratified) for DBD and DCD, with 10-hour CIT as the refer-
ence value; a comparison of 5-year graft survival rates and CIT 
for DCD donors aged 30, 45, and 60 years with DBD donors 
of the same ages; and an analysis of the results of the ESP, 
through which kidneys from donors 65 years and older are 
allocated to recipients in the same age range.15 In a first sen-
sitivity analysis, first WIT for DCD was categorized based on 
a median of 20 minutes, and the results were compared with 
the corresponding outcomes for DBD. In a second sensitivity 
analysis, the paired-kidney analysis of Kayler and colleagues8 
was replicated for DCD transplants with a CIT difference of 
at least 1 hour between kidneys. The results are presented as 
HRs with 95% confidence intervals (CIs). Significance levels 
were set at the 5% level. Analyses were conducted using R 
(version 3.3.2)16 with the “rms” package (version 5.1-0) and 
“mice” package (version 2.30). Figures were plotted using 
GraphPad Prism (version 7.0).
RESULTS
Baseline Characteristics
A total of 2153 transplants from 1266 DBD (58.8%) and 
887 controlled DCD (41.2%) donors were analyzed (see 
Figures 1 and 2 and Table 1). A higher percentage of DCD 
than DBD donors were discarded in the transplantation 
FIGURE 1. Flow diagram, with inclusion and exclusion criteria and 
patient counts. DBD, donation after brain death; DCD, donation after 
circulatory death.
FIGURE 2. Number of DCD and DBD donor registrations, effectuated donors for transplantation, and number of transplanted kidneys. More 
DCD donors are discarded in the selection process for transplantation than DBD donors. We were not able to retrospectively analyze the quality 
of discarded donor kidneys. DBD, donation after brain death; DCD, donation after circulatory death; Tx, kidney transplantations.
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selection process (29.1% vs 1.7%, respectively; Figure  1). 
Median kidney donor risk index was 1.38 (IQR 1.10–1.73). 
Median CIT was 16.2 hours (IQR 12.8–20.0) and lower for 
DBD (15.8 h IQR 12.1–19.9 vs 16.8 h IQR 13.9–20.0, P = 
0.003) than for DCD. For DBD kidneys, CIT ranged from 
3.4 hours to a maximum of 44.7 hours. For DCD kidneys, 
TABLE 1
Baseline characteristics
All DBD (n = 1266, 58.8%) DCD (n = 887, 41.2%)  
 Median (IQR)/N (%) Missing (%) Median (IQR)/N (%) Median (IQR)/N (%) P
Donor parameters      
 Age, y 52 (42–61) 0 52 (42–62) 52 (42–61) .961
 Sex, male 1134 (52.7%) 0 613 (48.4%) 521 (58.7%) <0.001
 Serum creatinine, mg/dL 0.78 (0.61–0.97) 9 (0.4%) 0.78 (0.61–1.00) 0.76 (0.60–0.95) <0.001
 Inotropic drugs, yes 489 (22.7%) 0 (0.0%) 326 (25.8%) 163 (18.4%) <0.001
 Hypertension, yes 536 (27.6%) 209 (9.7%) 347 (31.6%) 189 (22.3%) <0.001
 Diabetes, yes 106 (4.9%) 72 (3.3%) 62 (5.1%) 44 (5.0%) .920
 Cause of death  166 (7.7%)   <0.001
  CVA 1167 (58.5%)  770 (70.0%) 393 (44.3%)  
  Anoxia 175 (8.8%)  43 (3.9%) 132 (14.9%)  
  Other 668 (32.7%)  287 (26.1%) 362 (40.8%)  
 Height, cm 175 (168–180) 0 173 (168–180) 175 (170–180) <0.001
 Weight, kg 75 (66–85) 2 (0.0%) 75 (65–85) 78 (70–87) <0.001
 Smoking, yes 971 (47.9%) 124 (5.8%) 571 (48.2%) 400 (47.3%) .718
 KDRIa 1.38 (1.10–1.73) 276 (12.8%) 1.35 (1.06–1.70) 1.43 (1.15–1.77) .008
Transplant parameters      
 Total HLA mismatches 3 (2–3) 181 (8.4%) 3 (2–4) 3 (2–3) .741
 HLA-A mismatch  178 (8.3%)   .063
  0 651 (33.0%)  397 (34.2%) 254 (31.2%)  
  1 1034 (52.4%)  582 (50.2%) 452 (55.5%)  
  2 290 (14.7%)  181 (15.6%) 109 (13.4%)  
 HLA-B mismatch  178 (8.3%)   <0.001
  0 440 (22.3%)  294 (25.3%) 146 (17.9%)  
  1 1005 (50.9%)  516 (44.5%) 489 (60.0%)  
  2 530 (26.8%)  350 (27.6%) 180 (22.1%)  
 HLA-DR  186 (8.6%)   <0.001
  0 701 (35.6%)  451 (38.9%) 250 (30.9%)  
  1 1044 (53.1%)  544 (47.0%) 500 (61.8%)  
  2 222 (11.3%)  163 (14.1%) 59 (7.3%)  
 Cold ischemia time, h 16.2 (12.8–20.0) 267 (12.4%) 15.8 (12.1–19.9) 16.8 (13.9–20.0) .003
Anastomosis time, min 34.0 (27.0–41.0) 132 (6.1%) 34 (27–41) 33 (27–41) .679
Recipient parameters      
 Age, y 56 (46–64) 0 56 (46–65) 56 (46–64) .921
 Sex, male 1265 (58.8%) 0 730 (57.7%) 535 (60.3%) .230
 Dialysis vintage, y 3.7 (2.3–5.0) 72 (3.3%) 3.5 (2.2–4.9) 3.8 (2.7–5.0) <0.001
 Panel-reactive antibodiesb  28 (1.3%)   <0.001
  0 1868 (53.6%)  1069 (85.9%) 799 (90.8%)  
  >0–50 222 (10.4%)  144 (11.6%) 78 (8.9%)  
  >50 35 (1.6%)  32 (2.6%) 3 (0.3%)  
 BMI 25.3 (22.8–28.4) 125 (5.8%) 25.1 (22.6–28.2) 25.6 (22.9–28.7) .135
 Diabetes at transplantation 487 (23.3%) 62 (2.9%) 325 (26.4%) 162 (18.9%) <0.001
 Eurotransplant Senior Program allocations, yes 327 (15.2%) 0 211 (16.7%) 116 (13.1%) .024
 Primary kidney disease  0   <0.001
  Polycystic 333 (15.5%)  185 (14.6%) 148 (16.7%)  
  Glomerulonephritis 390 (18.1%)  191 (15.1%) 199 (22.4%)  
  Renal vascular 401 (18.6%)  252 (19.9%) 149 (16.8%)  
  Diabetes 355 (16.5%)  237 (18.7%) 118 (13.3%)  
  Chronic renal failure, etiology not known 317 (14.7%)  196 (15.5%) 121 (13.6%)  
  Pyelonephritis 102 (4.7%)  57 (4.5%) 45 (5.1%)  
  Other 255 (11.8%)  148 (11.7%) 107 (12.1%)  
 Follow-up, y 4.5 (2.9–7.0) 0 4.9 (3.0–7.0) 4.1 (2.7–7.0) .092
aKDRI, donor-only version was used.
b% panel-reactive antibodies at time of transplantation.
BMI, body mass index; CVA, cerebrovascular accident; DBD, donation after brain death; DCD, donation after circulatory death; HLA, human leukocyte antigen; IQR, interquartile range; KDRI, Kidney 
Donor Risk Index.
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FIGURE 3. One-year and 5-y graft survival by donor type (brain death and circulatory death donor kidneys) and CIT categories (<12, ≥12<18, 
≥18<24, and ≥24 h). Graft events are shown as (1) graft loss and return to dialysis, (2) patient death, or (3) alive, with functioning graft. Results 
are unadjusted. CIT, cold ischemia time; DBD, donation after brain death; DCD, donation after circulatory death.
A
B
FIGURE 4. Risk of 5-y graft failure (A) and death-censored graft failure (B) with every h of CIT, comparing DCD with DBD donor kidneys. 
Donation after brain death is the reference category in the DBD vs DCD comparison, in which HR > 1 indicates higher risk of graft failure for 
DCD donor kidneys, and HR < 1 indicates higher risk of graft failure for DBD. Cold ischemia time was modeled using a restricted cubic spline 
with knots at 12, 16, 20, and 24 h. Both unadjusted and adjusted results are shown. Adjusted results correspond to a donor aged 52 y, with 
last measured creatinine of 0.81 mg/dL, CVA as cause of death, 3 HLA mismatches, height of 175 cm, weight of 75 kg, nonsmoker, no inotropic 
drugs administered before donation, and no diabetes or hypertension, and a male recipient aged 56 y, with a BMI of 25.4, no recipient diabetes, 
PRA of 0, a median waiting time for transplantation of 3.7 y, 33 min of anastomosis, and not transplanted within the ESP. Confidence intervals 
are at the 95% interval. *indicate p<0.05 significant difference between DCD and DBD kidneys at the 5% level. BMI, body mass index; CIT, cold 
ischemia time; CVA, cerebrovascular accident; DBD, donation after brain death; DCD, donation after circulatory death; ESP, Eurotransplant 
Senior Program; HLA, human leukocyte antigen; HR, hazard ratio; PRA, panel-reactive antibody.
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the CIT range was 4.7–46.6 hours (Figure S2, SDC, http://
links.lww.com/TXD/A202). DCD donors were more likely 
to be male (P < .001), less likely to be users of inotropic 
drugs (P < .001), less likely to suffer from hypertension 
(P < .001), and had lower final serum creatinine (P < .001) 
than did DBD donors. In addition, DCD recipients were less 
frequently immunized (P < .001) and less likely to be diabetic 
(P < .001). The waiting time for a DCD donor kidney was also 
longer than that for a DBD kidney (P < .001). Recipients from 
the ESP program were more likely to receive a DBD donor 
kidney than a DCD donor kidney (P = 0.024).
Transplant Outcomes of Deceased Donor Types
The proportion of graft failures after 5 years attributable 
to graft loss and return to dialysis was 10.6% (95% CI, 9.3-
12), and 12.2% (95% CI, 10.8-13.7) was attributable to 
patient death as first event. For DCD kidneys, a higher pro-
portion—12.3% (95% CI, 10.1-14.6)—of graft failures were 
attributable to graft loss and return to dialysis, compared with 
9.5% (95% CI, 7.9-11.2, unadjusted P = 0.046) for DBD kid-
neys. Patient death as first event did not differ between DCD 
and DBD (12.8%, 95% CI, 10.5-15.4 vs 11.8%, 95% CI, 
10.0-13.8, unadjusted P = 0.593, respectively). Mortality at 5 
years, irrespective of graft failure, was 15.2% (95% CI, 13.6-
17.0) and did not differ between recipients of DCD and DBD 
donor kidneys (15.9%, 95% CI, 13.4-18.8 vs 14.8%, 95% 
CI, 12.8-17.1, unadjusted P = 0.603).
Associations of CIT and DCD Donor Type With 
Transplant Outcomes
Figure  3 depicts unadjusted 5-year graft survival rates 
according to donor type and CIT categories, including the pro-
portion of graft failures attributable to graft loss and return to 
dialysis or to patient death (Figure S3, SDC, http://links.lww.
com/TXD/A202 presents cumulative incidences over time). If 
CIT exceeded 24 hours, the 5-year survival rate with a func-
tioning graft was 58.8% for recipients of DCD kidneys, com-
pared with 72.4% for recipients of DBD kidneys. If CIT did 
not exceed 18 hours, no differences in graft failures between 
DCD and DBD donor kidneys were observed.
Four-knot restricted cubic splines were used to explore cut-
off values for CIT for the DCD donor type. Figure 4 illustrates 
the combined risk of transplanting DCD donor grafts with 
increasing CIT using DBD grafts as the reference category, 
which was held constant at an HR of 1 (the corresponding 
adjusted HRs can be found in Tables 2 and 3). For >12 hours 
of CIT, DCD kidneys demonstrated an increased hazard for 
of graft failure at 5 years when compared with DBD kid-
neys. This risk was significantly higher for DCD compared 
with DBD donor kidneys at a CIT of 22 hours (adjusted HR 
1.46; 95% CI, 1.01-2.09; P = 0.043). For DCD kidneys, an 
increase in CIT from 10 to 14 hours caused the 5-year risk of 
graft failure to increase by an adjusted HR of 1.88 (95% CI, 
1.01-3.50; P = 0.046; Figure 5). For DBD kidneys, the same 
increase in CIT led to a 5-year adjusted HR of graft failure of 
1.20 (95% CI, 0.89-1.62; P = 0.234).
At 15 hours or more of CIT, an increased hazard for death-
censored graft failure at 5 years was observed. At 23 hours or 
more of CIT, this hazard differed significantly for DCD and 
DBD donor kidneys (adjusted HR 1.67; 95% CI, 1.03-2.69; 
P = 0.036). No significant differences were found in terms of 
risk of 5-year mortality between DCD and DBD donor kid-
neys and increasing CIT.
Prolonged CIT and Donor Age
Figure 6 presents the combined risk of transplanting both 
DCD and DBD grafts with CIT for donors aged 30, 45, and 
60. At 19 hours of CIT, the risk of 5-year graft failure was 
significantly higher for recipients of kidneys from 60-year-
old DCD donors compared with recipients of kidneys from 
60-year-old DBD donors (adjusted HR 1.33; 95% CI, 1.00-
1.78; P = 0.045). At 25 hours of CIT, the risk of graft failure 
was also significantly higher for recipients of kidneys from 
45-year-old DCD donors than it was for recipients of kid-
neys from 45-year-old DBD donors (adjusted HR 1.42; 95% 
CI, 1.02-1.99; P = 0.002); this risk decreased after 25 hours 
of CIT. Additionally, within the ESP, DCD kidneys with high 
CIT showed an increased 5-year risk of graft failure when 
compared to DBD kidneys (Figure 7; Figure S4, SDC, http://
links.lww.com/TXD/A202 depicts the baseline differences 
between DBD and DCD in the ESP cohort). However, for 
30-year-old donors, there was no significant difference in risk 
TABLE 2
Hazard ratios for graft failure between donor types
Graft failure
CIT DBD DCD DCD vs DBD P
6 1.26 (0.66–2.40) 0.42 (0.08–2.37) 0.25 (0.03–2.29) 0.219
7 1.18 (0.74–1.91) 0.52 (0.15–1.89) 0.33 (0.06–1.93) 0.218
8 1.11 (0.82–1.52) 0.65 (0.28–1.50) 0.44 (0.12–1.65) 0.221
9 1.05 (0.91–1.21) 0.81 (0.54–1.21) 0.58 (0.23–1.46) 0.245
10 1.0 (ref) 1.0 (ref) 0.74 (0.39–1.42) 0.369
11 0.98 (0.88–1.10) 1.22 (0.88–1.67) 0.92 (0.54–1.57) 0.761
12 1.00 (0.84–1.20) 1.44 (0.86–2.43) 1.07 (0.64–1.78) 0.797
13 1.08 (0.86–1.36) 1.67 (0.91–3.04) 1.15 (0.73–1.80) 0.545
14 1.20 (0.89–1.62) 1.88 (1.01–3.50) 1.17 (0.80–1.69) 0.418
15 1.34 (0.91–1.97) 2.08 (1.10–3.94) 1.15 (0.80–1.66) 0.440
16 1.47 (0.95–2.29) 2.27 (1.18–4.37) 1.14 (0.77–1.70) 0.503
17 1.57 (1.01–2.43) 2.45 (1.28–4.71) 1.17 (0.80–1.70) 0.425
18 1.62 (1.07–2.44) 2.64 (1.41–4.95) 1.21 (0.88–1.67) 0.236
19 1.65 (1.12–2.42) 2.83 (1.53–5.22) 1.28 (0.95–1.71) 0.104
20 1.67 (1.15–2.43) 3.02 (1.64–5.57) 1.34 (0.97–1.86) 0.076
21 1.71 (1.17–2.49) 3.23 (1.74–5.98) 1.40 (0.98–2.01) 0.064
22 1.76 (1.21–2.56) 3.45 (1.86–6.38) 1.46 (1.01–2.09) 0.043
23 1.82 (1.26–2.63) 3.68 (2.00–6.79) 1.50 (1.06–2.13) 0.023
24 1.89 (1.31–2.73) 3.93 (2.14–7.24) 1.55 (1.10–2.17) 0.012
25 1.96 (1.35–2.85) 4.20 (2.28–7.75) 1.59 (1.13–2.23) 0.008
26 2.04 (1.39–3.00) 4.48 (2.41–8.33) 1.64 (1.15–2.33) 0.007
27 2.12 (1.41–3.17) 4.79 (2.55–8.99) 1.68 (1.14–2.47) 0.008
28 2.20 (1.43–3.38) 5.11 (2.68–9.74) 1.73 (1.13–2.65) 0.012
29 2.28 (1.44–3.62) 5.46 (2.81–10.61) 1.78 (1.11–2.86) 0.018
30 2.37 (1.44–3.89) 5.83 (2.93–11.58) 1.83 (1.08–1.08) 0.026
Adjusted hazard ratios and 95% confidence intervals from multivariable Cox regression with 
outcome of graft failure including interaction of donor type and CIT (with restricted cubic splines 
with 4 knots). Adjusted results correspond to a donor aged 52 y, with last measured creatinine 
of 0.81 mg/dL, CVA as a cause of death, 3 HLA mismatches, donor length of 175 cm and 75 kg, 
nonsmoking, no inotropic drugs given before donation, no diabetes and hypertension, male recipi-
ent aged 56 y, recipient BMI of 25.4, no recipient diabetes, PRA of 0%, with median waiting time 
for transplantation of 3.7 y, polycystic kidney disease as a cause of original kidney failure, not in 
Eurotransplant Senior Program, and 33 min of anastomosis time.
DBD is the reference category in the DBD vs DCD comparison, whereas HR > 1 indicates higher 
risk of graft failure for DCD donor kidneys, and HR < 1 indicates higher risk of graft failure for 
DBD. Presented are hazard ratios with 95% confidence intervals.
BMI, body mass index; CIT, cold ischemia time; CVA, cerebrovascular accident; DBD, donation 
after brain death; DCD, donation after circulatory death; HLA, human leukocyte antigen; HR, 
hazard ratio; PRA, panel-reactive antibody.
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of 5-year graft failure for DCD and DBD kidneys, irrespective 
of prolonged CIT. The additive effect of donor age was not 
found to be multiplicative; interaction between donor age and 
donor type was not significant (adjusted linear interaction, P 
= 0.317), and the interaction of CIT and donor type accord-
ing to different donor ages (CIT × donor type × donor age; 
adjusted linear triple interaction, P = 0.328).
Sensitivity Analyses
We sought to replicate the findings of 5-year graft sur-
vival, 5-year death-censored graft survival, and 5-year 
patient survival in a paired DCD kidney analysis to adjust 
for unmeasured donor quality confounders. DCD donors (n 
= 283) of both kidneys with CIT differences between kidneys 
of at least 1 hour were identified. Transplant characteristics 
(with the exception of CIT) and recipient characteristics 
did not differ between recipients of low- versus high-CIT 
groups. The DCD kidney recipients within the longer CIT 
group (median CIT 19.5, IQR 16.9–22.0) had a significantly 
higher risk of graft failure compared to the short CIT group 
(median CIT 14.6, IQR 11.8–17.2, with adjusted HR 1.40; 
95% CI, 1-1.98; P = 0.048). This did not differ significantly 
for death-censored rates of graft failure and mortality at 5 
years (Figure  8; see Table S1, SDC, http://links.lww.com/
TXD/A202 for baseline differences between low- vs high-
CIT groups).
Following we analyzed the interaction of CIT with donor 
type according to different donor WITs, of which only the 
time from asystole to cold perfusion could be retrieved. In 
DCD kidney recipients, the donor WIT was associated with 
a significantly higher hazard for death-censored graft failure 
(per min WIT increase, adjusted P = 0.0115). If DCD donor 
WIT was above 20 minutes, the 5-year risk of death-censored 
FIGURE 5. Risk of 5-y graft failure of transplanting DCD or DBD grafts 
with CIT, according to a reference time of 10 h. Adjusted results are 
shown, which correspond to the same values presented in Figure 4. 
CIT, cold ischemia time; DBD, donation after brain death; DCD, 
donation after circulatory death; HR, hazard ratio. * indicate p<0.05.
FIGURE 6. Risk of 5-y graft failure of transplanting DCD grafts with 
CIT according to a donor age of 30, 45, and 60 y, with each category 
compared with the same age of a DBD donor kidney as the reference 
category. Only adjusted results are shown, which correspond to the 
same values presented in Figure  4. CIT, cold ischemia time; DBD, 
donation after brain death; DCD, donation after circulatory death; HR, 
hazard ratio.
TABLE 3
Hazard ratios for death-censored graft failure between 
donor types
Death-censored graft failure
CIT DBD DCD DCD vs DBD P
6 0.60 (0.34–1.05) 0.44 (0.18–1.04) 0.53 (0.07–3.98) 0.541
7 0.68 (0.45–1.04) 0.54 (0.28–1.03) 0.58 (0.10–3.36) 0.543
8 0.77 (0.59–1.02) 0.66 (0.43–1.02) 0.63 (0.14–2.85) 0.545
9 0.88 (0.76–1.01) 0.81 (0.66–1.01) 0.68 (0.19–2.43) 0.551
10 1.0 (ref) 1.0 (ref) 0.73 (0.26–2.09) 0.563
11 1.14 (0.99–1.31) 1.23 (0.99–1.53) 0.79 (0.35–1.82) 0.588
12 1.29 (0.98–1.71) 1.51 (0.98–2.33) 0.86 (0.45–1.64) 0.648
13 1.47 (0.97–2.23) 1.86 (0.98–3.54) 0.93 (0.55–1.58) 0.79
14 1.66 (0.97–2.83) 2.27 (0.98–5.21) 1.00 (0.61–1.66) 0.987
15 1.85 (0.99–3.44) 2.72 (1.02–7.23) 1.08 (0.64–1.82) 0.778
16 2.03 (1.05–3.92) 3.18 (1.10–9.18) 1.15 (0.68–1.93) 0.602
17 2.19 (1.15–4.18) 3.61 (1.24–10.53) 1.21 (0.77–1.92) 0.412
18 2.31 (1.24–4.30) 4.00 (1.41–11.28) 1.27 (0.86–1.88) 0.233
19 2.39 (1.30–4.41) 4.34 (1.60–11.74) 1.33 (0.89–1.98) 0.159
20 2.45 (1.32–4.52) 4.65 (1.77–12.19) 1.40 (0.89–2.20) 0.15
21 2.47 (1.33–4.58) 4.95 (1.93–12.73) 1.47 (0.90–2.41) 0.122
22 2.46 (1.33–4.56) 5.25 (2.07–13.34) 1.57 (0.96–2.57) 0.075
23 2.44 (1.32–4.52) 5.55 (2.20–14.00) 1.67 (1.03–2.69) 0.036
24 2.41 (1.29–4.50) 5.85 (2.32–14.76) 1.78 (1.11–2.85) 0.017
25 2.38 (1.25–4.55) 6.17 (2.43–15.65) 1.90 (1.16–3.10) 0.01
26 2.36 (1.19–4.67) 6.51 (2.54–16.67) 2.03 (1.19–3.46) 0.01
27 2.33 (1.12–4.84) 6.87 (2.64–17.86) 2.17 (1.19–3.94) 0.011
28 2.30 (1.04–5.06) 7.24 (2.73–19.22) 2.31 (1.18–4.54) 0.015
29 2.27 (0.97–5.34) 7.64 (2.81–20.78) 2.47 (1.15–5.28) 0.02
30 2.25 (0.89–5.66) 8.06 (2.88–22.56) 2.63 (1.12–6.19) 0.026
Adjusted hazard ratios and 95% confidence intervals from multivariable Cox regression with 
outcome of graft failure including interaction of donor type and CIT (with restricted cubic splines 
with 4 knots), for outcome death-censored graft failure. Adjusted results correspond to the same 
values as stated in Table 2.
CIT, cold ischemia time; DBD, donation after brain death; DCD, donation after circulatory death.
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graft failure increased for every hour of CIT, with a significant 
increase after 23 hours compared with DBD (adjusted HR 
2.00; 95% CI, 1.04-3.80; P = 0.035; see Figure 9).
DISCUSSION
Higher CIT is associated with an increased risk of graft 
failure for both DCD and DBD donor kidney recipients. 
However, the risk of graft failure for recipients of DCD donor 
kidneys increased more for each extra hour of CIT than it did 
for DBD donor kidneys: with a reference CIT of 10 hours, the 
risk of graft failure for DCD kidneys increased after just 14 
hours, while the same risk for DBD kidneys did not increase 
until at least 17 hours of CIT. With DBD as a reference cat-
egory, we observed an increased risk of graft failure in DCD 
kidneys as compared with DBD kidneys after 12 hours of 
CIT, and this risk was significantly different after 22 hours. 
This additional risk for DCD kidneys with increased CIT as 
compared with DBD kidneys was also observed for the non-
composite outcome of death-censored graft failure but not 
for mortality. The risk of graft failure was significantly higher 
at 19 hours of CIT for recipients of kidneys from 60-year-
old DCD donors than it was for recipients of kidneys from 
60-year-old DBD donors. The same additional risk of graft 
failure was seen in the ESP for DCD donor kidney recipients. 
In contrast, increased CIT led to no difference in outcomes 
between 30-year-old DCD and DBD kidneys.
The Netherlands have a large controlled DCD donor pool, 
which allows for the analysis of differences in graft survival 
between DCD and DBD donors and between results from 
recipients of younger and older donor kidneys.17 However, 
identifying the precise CIT cutoff value which DCD kidney 
FIGURE 7. Risk of 5-y graft failure of transplanting DCD or DBD grafts with associations of CIT in the ESP. Cold ischemia time was modeled 
with a restricted cubic spline with 3 internal knots at 12, 15, and 20 h. For donor kidneys provided by the ESP, the median CIT was 15.8 h. 
Adjusted results are shown, which correspond to a donor aged 68 y, with last measured creatinine of 0.87 mg/dL, CVA as a cause of death, 
four HLA mismatches, height of 172 cm, weight of 75 kg, nonsmoker, no inotropic drugs administered before donation, and no diabetes and 
hypertension, and a male recipient aged 69 y, BMI of 25.9, no diabetes, PRA of 0, with a median waiting time for transplantation of 3.3 y, and 
34 min of anastomosis. Confidence intervals are at the 95%. BMI, body mass index; CIT, cold ischemia time; CVA, cerebrovascular accident; 
DBD, donation after brain death; DCD, donation after circulatory death; ESP, Eurotransplant Senior Program; HLA, human leukocyte antigen; 
HR, hazard ratio; PRA, panel-reactive antibody.
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outcomes worsen relative to those of DBD were possibly sub-
ject to a lack of power in the analysis. The significant HR 
between DBD and DCD kidneys at 22 hours of CIT represents 
an estimated 7% (79.2–72.2) difference in graft survival after 
5 years (corresponding to a relatively healthy donor aged 52 
y and recipient aged 56 y). However, a trend of higher risk of 
graft failure was observed after 12 hours of CIT; for example, 
after 18 hours, DBD recipients were 5% (82.3–77.4) more 
likely to survive, which suggests clinical relevance despite not 
being statistically significant.18 It is unclear why exactly DCD 
kidneys demonstrate an earlier onset and more severe risk for 
worse graft survival with higher CIT; however, donor WIT 
may contribute to the differences in terms of risk of graft fail-
ure due to extra ischemia-mediated cellular damage.7 If we 
model CIT with a hypothesized donor WIT of 5 minutes in 
DCD donors and impute a WIT of 0 minutes in DBD donors, 
the correlation between CIT and donor type disappears, sug-
gesting that the impact of CIT is exacerbated by donor WIT 
in DCD kidneys. However, functional donor WIT, including 
warm ischemic injury during the agonal phase when systolic 
blood pressure is below 50 mm Hg, is not registered in the 
NOTR and therefore could not be taken into account in this 
analysis.
Our results confirm the findings of Summers and col-
leagues,6 who found in a UK cohort (2005–2010, n = 5895) 
that increased CIT (≥24 h) was associated with decreased 
graft survival in DCD donor kidney recipients when com-
pared with their DBD counterparts. Higher donor age was 
associated with decreased graft survival in recipients of 
deceased donor kidneys but showed no difference between 
DCD and DBD kidneys. When we did identify clinically rel-
evant differences between donor types at the age of 60 years, 
we analyzed the interaction between the continuous vari-
able CIT and donor type according to different donor ages 
(CIT × donor type × donor age). A previous Dutch study by 
van Vliet and colleagues,19 using data from the same NOTR 
(1990–2007), found significantly better rates of graft survival 
at under 16 hours of CIT for DCD kidneys and under 20 
FIGURE 9. Influence of donor WIT on interaction with CIT in DCD 
kidneys as compared with DBD. Donor WIT was only registered from 
asystole to cold perfusion (as functional WIT could not be extracted 
from the national registry). CIT, cold ischemia time; DBD, donation 
after brain death; DCD, donation after circulatory death; HR, hazard 
ratio; WIT, warm ischemia time.
FIGURE 8. Paired DCD kidney analysis. Donation after circulatory death pair kidneys with at least 1 h of CIT difference were compared. 
Transplant and recipient characteristics were compared between the pairs, and no significant differences were observed. On the 
composite endpoint of graft survival, we found a significant difference between the low- and high-CIT pairs, but this was not significant 
for death-censored graft survival. CIT, cold ischemia time; DBD, donation after brain death; DCD, donation after circulatory death.
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hours of CIT for DBD kidneys. The median CIT (23.7 h) in 
the study conducted by van Vliet et al was higher than that 
of the data analyzed and categorized here. In another Dutch 
study by Roodnat et al,20 CIT was found to be independently 
and significantly associated with death-censored graft fail-
ure, with the highest risk in the first week after transplanta-
tion. However, this study included both recipients from living 
related kidney donors and deceased donors, and outcomes 
were not presented separately.
The effects of CIT and donor type on long-term kidney 
transplantation have not been studied in the United States.12 
This was confirmed by a recent paired-kidney analysis from 
the United States (1989–2013, n = 6276) that found similar 
graft survival rates between kidney pairs with a delta CIT of 
1 hour or higher.8 Our findings suggest that, given the avail-
ability of a DCD donor kidney with a WIT that is considered 
acceptable, the additional cold ischemia injury caused by at 
least one extra hour does affect the long-term risk of graft 
failure. Another US cohort showed no significant difference in 
outcome after kidney transplantation between DCD and non-
DCD donors, and this association was not affected by ECD 
status.21 This may reflect different approaches to selecting 
DCD donor kidneys for transplantation, as DCD kidneys rep-
resent a smaller proportion of transplants in the United States 
compared with the United Kingdom and the Netherlands.22,23 
Additionally, a large proportion of kidneys in this cohort come 
from DCD kidneys from elderly donors with prolonged WITs.
The differences among the findings obtained in these 
countries may be due to allocation and policy differences, 
and ethical principles for deceased donor procurement. In 
France, as many other countries, controlled DCD donors are 
not accepted for organ transplantation.24,25 Similarly to our 
research, a French study (n = 4777) analyzed CIT as a con-
tinuous variable, finding that the risk of graft failure in DBD 
donor recipients was multiplied by 1.013 for each extra hour 
of CIT.26 Many other studies have been unable to compare 
outcomes between controlled DCD and DBD kidneys, indi-
cating that, irrespective of donor source, CIT above a certain 
categorical limit is associated with graft failure.27-32
The primary strength of our study is the national cohort in 
a high-quality database that provides thorough data on mor-
tality after graft loss. In terms of limitations, center-specific 
differences in demographics, treatment, or outcomes were not 
able to be factored into our analysis. Furthermore, since DCD 
donor kidneys are sometimes classified as marginal and there-
fore (re)allocated to marginal recipients, there may still exist 
residual confounding factors, despite the adjustment of many 
confounders in the analysis. The present analysis included 
first-time transplanted recipients only.
In conclusion, our study indicates that the association of 
CIT and graft failure was stronger for DCD donor kidneys 
compared with DBD. This was not true if kidneys were from 
younger (ie, 30-y-old) DCD donors. While these data may 
help to optimize the scheduling of transplant surgery, future 
studies on machine perfusion cohorts are necessary to identify 
the causes of the differential effects of CIT.
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